Growing prevalence of Alzheimer's is acting as a driving force for memantine market
Memantine
is used for improving blood circulation, treating allergies, curing
hemorrhoids, and even healing ulcers. It has anti-coagulant properties which
makes it ideal for treating various ailments. It can also be used to treat
other diseases including infections and even Alzheimer's disease. The only
known side effect of Memantine is diarrhea, but this is an uncommon occurrence.
The
growing prevalence of Alzheimer's around the globe is a key factor is driving
the growth of the memantine
market. According to the Alzheimer's Association, more than 6 million
Americans of all ages have Alzheimer's. An estimated 6.2 million Americans age
65 and older are living with Alzheimer's dementia in 2021. Seventy-two percent
are age 75 or older. One in 9 people age 65 and older (11.3%) has Alzheimer's
dementia. memantine is a drug that is used to treat Alzheimer's. Moreover, the
growing aging population is also increasing the risk of Alzheimer's which is
further propelling the growth of the memantine market over the forecast period. According to the United Nation, the global
population aged 60 years or over numbered 962 million in 2017, more than twice
as large as in 1980 when there were 382 million older persons worldwide. The
number of older persons is expected to double again by 2050 when it is
projected to reach nearly 2.1 billion.
North
America is projected to gain significant growth over the forecast period and
this is attributed to the increasing number of FDA approval for the launch new
and effective drug for treating Alzheimer's. For instance, in March 2020, ANI
Pharmaceuticals, Inc. announced that it has received the approval of the Company's
abbreviated new drug application (ANDA) from the U.S. Food and Drug
Administration (FDA) for Memantine Hydrochloride Extended-Release Capsules 7 mg,
14 mg, 21 mg and 28 mg.
Key Developments:
1. In February 2018, Pharma major
Lupin announced the launch of its Memantine Hydrochloride Extended-Release
Capsules, 7mg, 14mg, 21mg, 28mg having received approval from the United States
Food and Drug Administration (FDA). Lupin’s Memantine Hydrochloride ER capsules
7mg, 14mg, 21mg, 28mg are the generic equivalents of Allergan’s Namenda XR®
capsules
2. In September 2019, AbbVie
announced the $63 billion acquisition of Allergan, which would make the new
company a $48 billion enterprise. While AbbVie’s current top-selling drug is
Humira (adalimumab), it has recently invested in neuroscience, investigating
potential drugs for Parkinson's disease, multiple sclerosis, and Alzheimer's
disease.
Comments
Post a Comment